Press Releases Keyword Search Year None202420232022202120202019201820172016201520142013 December 12, 2024 Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years December 9, 2024 Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting November 6, 2024 Editas Medicine to Participate in Upcoming Investor Conferences November 4, 2024 Editas Medicine Announces Third Quarter 2024 Results and Business Updates October 22, 2024 Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update October 21, 2024 Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics October 18, 2024 Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept October 3, 2024 Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust August 28, 2024 Editas Medicine to Participate in Upcoming Investor Conferences August 7, 2024 Editas Medicine Announces Second Quarter 2024 Results and Business Updates Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
December 12, 2024 Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
December 9, 2024 Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
October 22, 2024 Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
October 21, 2024 Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
October 18, 2024 Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
October 3, 2024 Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
